Brii Biosciences Limited (Brii Bio) filed its monthly return for March 2026, detailing modest equity movements while keeping authorised capital unchanged.

Authorised Capital • Authorised share capital stayed at 1.20 billion ordinary shares with a par value of USD 0.000005, totaling USD 6,000.

Issued and Treasury Shares • Issued shares (excluding treasury) rose by 218,796 to 721.76 million. • Treasury stock was unchanged at 12.72 million shares, leaving total issued shares at 734.48 million. • The company confirmed that the public float continues to exceed the 25 % minimum prescribed by the Hong Kong Stock Exchange.

Breakdown of New Issuance 1. Share Options – 178,000 new shares were issued through option exercises, generating HKD 0.16 million in cash proceeds. – Exercises comprised 120,000 shares under the Pre-IPO Share Incentive Scheme and 58,000 shares under the 2023 Share Option Scheme.

2. Share Award Schemes – 40,796 new shares were granted: 25,050 via the Post-IPO Share Award Scheme and 15,746 via the 2023 Share Award Scheme. – During the month, 8,629 restricted share units (RSUs) were cancelled and 1,000 RSUs lapsed; these events did not affect issued share count.

Outstanding Equity Instruments (end-March 2026) • Options: – Pre-IPO Share Incentive Scheme: 5.85 million options outstanding. – Post-IPO Share Option Scheme: 10.44 million options outstanding. – 2023 Share Option Scheme: 25.23 million options outstanding, with capacity to issue up to 42.79 million additional shares under the plan.

• Share Awards: – Post-IPO Share Award Scheme: 1.37 million shares available for future grant. – 2023 Share Award Scheme: 3.06 million shares available for future grant.

No warrants, convertible securities, or other equity-linked instruments were outstanding or exercised during the month.

The filing was signed by Joint Company Secretary Dr. Ankang Li on 8 April 2026.